Abstract
Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.
| Original language | English |
|---|---|
| Journal | Expert Review of Clinical Pharmacology |
| Volume | 9 |
| Issue number | 2 |
| Pages (from-to) | 241-65 |
| Number of pages | 25 |
| ISSN | 1751-2433 |
| DOIs | |
| Publication status | Published - 1 Feb 2016 |
Keywords
- Animals
- Blood Glucose
- Diabetes Mellitus, Type 2
- Glucagon
- Glucagon-Like Peptide 1
- Glucagon-Like Peptide-1 Receptor
- Humans
- Hypoglycemic Agents
- Insulin
- Journal Article
- Review
